Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $1.3 million.

  • 4D Molecular Therapeutics' Depreciation & Amortization (CF) rose 596.64% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 182.44%. This contributed to the annual value of $4.7 million for FY2024, which is 1068.03% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Depreciation & Amortization (CF) stood at $1.3 million, which was up 596.64% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) registered a high of $1.3 million during Q3 2025, and its lowest value of $370000.0 during Q2 2021.
  • In the last 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) had a median value of $1.0 million in 2023 and averaged $855842.1.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Depreciation & Amortization (CF) soared by 16000.0% in 2022 and then crashed by 1040.07% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $390000.0 in 2021, then skyrocketed by 160.0% to $1.0 million in 2022, then increased by 8.68% to $1.1 million in 2023, then decreased by 0.54% to $1.1 million in 2024, then increased by 15.05% to $1.3 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.3 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.1 million in Q1 2025.